History
March 2020
ViraTherapeutics inaugurates new laboratory in Rum near Innsbruck
ViraTherpeutics inaugurates new facilities in Rum near Innsbruck comprising laboratory and office space for its growing R&D and management staff.
September 2018
Boehringer Ingelheim acquires all shares of ViraTherapeutics
Boehringer Ingelheim acquires all shares of ViraTherapeutics to develop next generation viral-based immuno-oncology therapies. The total transaction value of EUR 210 million is based on an option and share purchase agreement signed between the companies in August 2016.
March 2018
ViraTherapeutics starts second oncolytic virus development program with Boehringer Ingelheim
ViraTherapeutics announces the expansion of its collaboration with Boehringer Ingelheim with a second oncolytic virus program. The new development program is an oncolytic virus, stemming from ViraTherapeutics’ technology platform. The Vesicular Stomatitis Virus (VSV) will be armed with an additional immunotherapeutic component from Boehringer Ingelheim.
May 2017
ViraTherapeutics appoints Dr. Heinz Schwer as CEO
ViraTherapeutics announces the appointment of Dr. Heinz Schwer as CEO. He takes over the position from interim CEO and co-founder Prof. Dr. Dorothee von Laer, who will remain a scientific advisor.
May 2017
Grand opening of Christian Doppler Laboratory for Viral Immunotherapy of Cancer at the Medical University of Innsbruck
ViraTherapeutics and Boehringer Ingelheim partner with the Medical University of Innsbruck in the new Christian Doppler Laboratory for cancer viro-immunotherapy. Generous funding is provided by the Christian Doppler Research Association.
September 2016
ViraTherapeutics and Boehringer Ingelheim announce long-term collaboration
ViraTherapeutics and Boehringer Ingelheim announce a new long-term collaboration to develop a next generation oncolytic virus platform and the lead candidate VSV-GP. The potential transaction value is up to EUR 210 million and includes co-funding of development activities and an option to acquire ViraTherapeutics.
August 2016
Closing of Series B financing round
ViraTherpeutics raises 4.1 million Euro in a series B financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF), EMBL Ventures, Empl Privatstiftung and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.
November 2015
ViraTherapeutics inaugurates new laboratory in Innsbruck
ViraTherpeutics inaugurates new facilities in Innsbruck comprising laboratory and office space for its R&D and management staff.
June 2015
Closing of Series A financing round
ViraTherapeutics raises 5.2 million Euro in a series A financing round. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and EMBL Ventures, and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.
December 2014
ViraTherapeutics receives Research Studio Austria grant
The financing was awarded by the Austrian Research Promoting Agency (FFG). In the Research Studio Austria "ViraVet" ViraTherapeutics will collaborate with the verterinary faculties of the universities of Vienna and Munich.
November 2014
ViraTherapeutics receives Seedfinancing grant from aws
The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.
September 2014
Empl Privatstiftung joins as a Business Angel
Empl Privatstiftung invests in ViraTherapeutics as a Business Angel.
July 2013
ViraTherapeutics wins 2nd prize of Science4Life Venture Cup
The second prize of the Science4Life Venture Cup 2013 was awarded to ViraTherapeutics.
June 2013
European patent granted for VSV-GP technology
A patent protecting ViraTherapeutics' proprietary oncolytic virus platform was granted by the European Patent Office. Prior to that, the patent had already been granted in other countries.
April 2013
ViraTherapeutics founded as a GmbH
ViraT was founded as a spin-out of the Medical University of Innsbruck by Prof. Dr. Dorothee von Laer, Head of the Division of Virology at the university, and Dr. Ludwig Weiss. All patents and patent applications for the VSV-GP technology were transferred to ViraTherapeutics.
January 2013
ViraTherapeutics receives preseed grant from aws
The aws is an Austrian federal development and financing bank for the promotion and financing of companies with specialized programms for high tech start-up companies.
October 2012
ViraTherapeutics wins Best of Biotech
ViraTherapeutics business concept won the first prize of the international Life Science business plan competition "Best of Biotech".
October 2012
ViraTherapeutics wins Tyrolean Innovation Award
ViraTherapeutics' business concept was awarded with the "Innovation Award" of the Tyrolean Chamber of Commerce in the category "Best Concept".
June 2012
ViraTherapeutics wins 1st prize of AdventureX
ViraTherapeutics business concept won the 1st prize of the Tyrolean business plan competition "AdventureX".